120 related articles for article (PubMed ID: 23567961)
21. Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.
Zirm E; Spies-Weisshart B; Heidel F; Schnetzke U; Böhmer FD; Hochhaus A; Fischer T; Scholl S
Br J Haematol; 2012 May; 157(4):483-92. PubMed ID: 22409268
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of sorafenib in FLT3-driven leukemic cells.
Auclair D; Miller D; Yatsula V; Pickett W; Carter C; Chang Y; Zhang X; Wilkie D; Burd A; Shi H; Rocks S; Gedrich R; Abriola L; Vasavada H; Lynch M; Dumas J; Trail PA; Wilhelm SM
Leukemia; 2007 Mar; 21(3):439-45. PubMed ID: 17205056
[TBL] [Abstract][Full Text] [Related]
23. FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations FLT3 in AML: much more to learn about biology and optimal targeting.
Giles FJ
Leuk Res; 2006 Dec; 30(12):1469-70. PubMed ID: 16631251
[TBL] [Abstract][Full Text] [Related]
24. Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
Wodicka LM; Ciceri P; Davis MI; Hunt JP; Floyd M; Salerno S; Hua XH; Ford JM; Armstrong RC; Zarrinkar PP; Treiber DK
Chem Biol; 2010 Nov; 17(11):1241-9. PubMed ID: 21095574
[TBL] [Abstract][Full Text] [Related]
25. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY
J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959
[TBL] [Abstract][Full Text] [Related]
26. SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants.
Cao ZX; Liu JJ; Zheng RL; Yang J; Zhong L; Xu Y; Wang LJ; Zhang CH; Wang BL; Ma S; Wang ZR; Xie HZ; Wei YQ; Yang SY
Leukemia; 2012 Aug; 26(8):1892-5. PubMed ID: 22402607
[No Abstract] [Full Text] [Related]
27. Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
Lin WH; Hsieh SY; Yen SC; Chen CT; Yeh TK; Hsu T; Lu CT; Chen CP; Chen CW; Chou LH; Huang YL; Cheng AH; Chang YI; Tseng YJ; Yen KR; Chao YS; Hsu JT; Jiaang WT
Bioorg Med Chem; 2011 Jul; 19(14):4173-82. PubMed ID: 21708468
[TBL] [Abstract][Full Text] [Related]
28. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
Wang D; Tang F; Wang S; Jiang Z; Zhang L
Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
[TBL] [Abstract][Full Text] [Related]
29. Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase.
Komeno Y; Kurokawa M; Imai Y; Takeshita M; Matsumura T; Kubo K; Yoshino T; Nishiyama U; Kuwaki T; Kubo K; Osawa T; Ogawa S; Chiba S; Miwa A; Hirai H
Leukemia; 2005 Jun; 19(6):930-5. PubMed ID: 15815726
[TBL] [Abstract][Full Text] [Related]
30. Discovery of thienopyrimidine-based FLT3 inhibitors from the structural modification of known IKKβ inhibitors.
Park CH; Lee C; Yang JS; Joe BY; Chun K; Kim H; Kim HY; Kang JS; Lee JI; Kim MH; Han G
Bioorg Med Chem Lett; 2014 Jun; 24(12):2655-60. PubMed ID: 24813730
[TBL] [Abstract][Full Text] [Related]
31. Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia.
Zhong Y; Qiu RZ; Sun SL; Zhao C; Fan TY; Chen M; Li NG; Shi ZH
J Med Chem; 2020 Nov; 63(21):12403-12428. PubMed ID: 32659083
[TBL] [Abstract][Full Text] [Related]
32. Activity of 2,6,9-trisubstituted purines as potent PDGFRα kinase inhibitors with antileukaemic activity.
Řezníčková E; Gucký T; Kováčová V; Ajani H; Jorda R; Kryštof V
Eur J Med Chem; 2019 Nov; 182():111663. PubMed ID: 31514019
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
Siendones E; Barbarroja N; Torres LA; Buendía P; Velasco F; Dorado G; Torres A; López-Pedrera C
Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
[TBL] [Abstract][Full Text] [Related]
34. Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance.
Fischer T; Najjar A; Totzke F; Schächtele C; Sippl W; Ritter C; Hilgeroth A
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1-8. PubMed ID: 29098884
[TBL] [Abstract][Full Text] [Related]
35. 3,4-Diarylmaleimides-a novel class of kinase inhibitors-effectively induce apoptosis in FLT3-ITD-dependent cells.
Heidel FH; Mack TS; Razumovskaya E; Blum MC; Lipka DB; Ballaschk A; Kramb JP; Plutizki S; Rönnstrand L; Dannhardt G; Fischer T
Ann Hematol; 2012 Mar; 91(3):331-44. PubMed ID: 21881825
[TBL] [Abstract][Full Text] [Related]
36. A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations.
Kiyoi H; Shiotsu Y; Ozeki K; Yamaji S; Kosugi H; Umehara H; Shimizu M; Arai H; Ishii K; Akinaga S; Naoe T
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4575-82. PubMed ID: 17671144
[TBL] [Abstract][Full Text] [Related]
37. MR22388, a novel anti-cancer agent with a strong FLT-3 ITD kinase affinity.
Rochais C; Cresteil T; Perri V; Jouanne M; Lesnard A; Rault S; Dallemagne P
Cancer Lett; 2013 Apr; 331(1):92-8. PubMed ID: 23268332
[TBL] [Abstract][Full Text] [Related]
38. Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.
Wang Q; Liu F; Qi S; Qi Z; Yan XE; Wang B; Wang A; Wang W; Chen C; Liu X; Jiang Z; Hu Z; Wang L; Wang W; Ren T; Zhang S; Yun CH; Liu Q; Liu J
Eur J Med Chem; 2018 Apr; 150():366-384. PubMed ID: 29544149
[TBL] [Abstract][Full Text] [Related]
39. [Effects of FMS-like tyrosine kinase 3 targeted RNA interference on proliferation and apoptosis of acute monocytic leukemia cell line THP-1].
Lu J; Sheng GY; Zou X; Xu XJ; Zhao XM; Bai ST; Xu PR
Zhonghua Er Ke Za Zhi; 2007 Aug; 45(8):615-9. PubMed ID: 18021537
[TBL] [Abstract][Full Text] [Related]
40. Identification of 2-acylaminothiophene-3-carboxamides as potent inhibitors of FLT3.
Patch RJ; Baumann CA; Liu J; Gibbs AC; Ott H; Lattanze J; Player MR
Bioorg Med Chem Lett; 2006 Jun; 16(12):3282-6. PubMed ID: 16580199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
